Financial Performance - Operating revenue for the current period was ¥114,287,205, representing a year-on-year increase of 5.75%[7] - Net profit attributable to shareholders decreased by 37.17% to ¥3,769,212.7 compared to the same period last year[7] - The basic earnings per share fell by 46.27% to ¥0.0072, while diluted earnings per share also decreased by the same percentage[7] - The company reported total operating revenue of CNY 301,069,330.26, a decrease of 11.22% compared to the same period last year[22] - Net profit attributable to shareholders was CNY 10,548,260.63, down 55.49% year-on-year[22] - The company reported a net profit margin improvement, with retained earnings at CNY 122,877,101.18 compared to CNY 129,758,258.26 in the previous period[52] - The total profit for the third quarter was CNY 4,365,565.00, down from CNY 7,008,213.04, reflecting a decline of about 37.5%[56] - The total profit for Q3 2020 was CNY 12.28 million, down 54.8% from CNY 27.16 million in Q3 2019[68] Cash Flow and Assets - The net cash flow from operating activities improved significantly, showing a 161.40% increase to ¥33,666,270[7] - The cash inflow from operating activities for the period was CNY 273,917,078.34, compared to CNY 202,614,268.60 in the previous period, representing a growth of approximately 35.2%[69] - The total cash outflow from investing activities was CNY 120,247,612.20, compared to CNY 134,285,688.90 in the previous period, indicating a decrease of about 10.5%[71] - The total cash and cash equivalents at the end of the period amounted to CNY 51,987,950.93, slightly down from CNY 54,365,916.23 at the end of the previous period[75] - Total assets at the end of the reporting period reached ¥1,403,113,232.85, an increase of 6.68% compared to the previous year[7] - As of September 30, 2020, the company's total current assets amounted to approximately CNY 490.33 million, an increase from CNY 474.11 million at the end of 2019[46] Liabilities and Equity - The company's net assets attributable to shareholders decreased by 0.49% to ¥984,196,581.94[7] - Total liabilities increased to CNY 416,749,651.14 from CNY 322,159,811.22 year-over-year[52] - Current liabilities rose to CNY 338,204,943.83, up from CNY 242,944,983.18 in the previous period[52] - The company's total equity decreased to CNY 987,235,706.03 from CNY 996,573,716.93[52] - The total equity attributable to shareholders of the parent company is CNY 989,082,880.93, indicating strong financial health[80] Inventory and Receivables - Inventory rose by 30.64% to ¥302,590,458.49, attributed to decreased sales during the COVID-19 pandemic[18] - Accounts receivable financing decreased by 81.22% to ¥12,311,132.31 from ¥65,551,538.90 due to the endorsement transfer of bank acceptance bills[18] - Accounts receivable decreased to CNY 88.52 million from CNY 102.40 million year-over-year, indicating improved collection efficiency[46] - Inventory levels increased significantly to CNY 302.59 million from CNY 231.62 million, reflecting a strategic buildup in anticipation of market demand[46] Research and Development - The company is advancing a new artificial meat project, with structural research nearly complete and equipment procurement underway[27] - The company is developing a super-low endotoxin gelatin preparation process, aimed at enhancing the medical device industry[29] - Research and development expenses were CNY 2,633,012.40, slightly down from CNY 2,648,127.86, indicating a focus on maintaining R&D investment[59] - Research and development expenses were CNY 8.34 million, slightly up from CNY 8.16 million year-over-year, showing continued investment in innovation[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,117, with the largest shareholder holding 27.37%[10] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12] - The company repurchased part of its restricted stock, reducing treasury stock by 50% to ¥2,536,560.00[19] Regulatory and Compliance - The company adjusted its financial statements to reflect the new revenue recognition standards, impacting contract liabilities and other current liabilities[81] - The company implemented new revenue recognition standards starting in 2020, adjusting advance payments to contract liabilities and other current liabilities[85] - The third quarter report was not audited[86]

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total annual gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company's construction of a 2,000-ton collagen production project has been completed, resulting in a 48.69% decrease in construction in progress compared to the beginning of the period[45]. - The annual production capacity for gelatin reached 13,500 tons, while collagen protein capacity was 3,000 tons following the launch of the fundraising project[61]. - The company is currently constructing several projects, including a 20,000-ton collagen protein peptide supplement production project, which is in the preparation stage[92]. - The company has committed to an investment project for the construction of a new gelatin production facility with an annual capacity of 3,500 tons, with a total investment of CNY 25,357 million, achieving 98.83% of the planned investment by the end of the reporting period[97]. Financial Performance - The company reported total operating revenue of ¥186,782,124.41, a decrease of 19.15% compared to the same period last year[26]. - Net profit attributable to shareholders was ¥6,779,047.92, down 61.70% year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥3,844,553.20, a decline of 74.09% compared to the previous year[26]. - Basic earnings per share decreased to ¥0.0129, down 64.17% from the previous year[26]. - The weighted average return on net assets was 0.69%, a decrease of 1.35% compared to the previous year[26]. Market Strategy and Product Development - The company aims to strengthen its brand "Yuan Su Bone Peptide" in the senior market and has introduced new products such as "multi-flavor collagen peptide powder" and "fish collagen" to diversify its product line[8]. - The company is focusing on expanding into high-growth health markets, including nutrition and bone health, to capitalize on consumer trends[7]. - The company is enhancing its online marketing efforts, expanding into cross-border e-commerce and self-media channels to optimize its sales system[62]. - The company is focusing on market expansion in the fields of medicine, health, food, and beauty, aiming for diversified applications of collagen[60]. - The company has successfully developed new products, including a composite emulsifier and a new artificial meat project, indicating a diversification of collagen applications[51]. Challenges and Risks - The company has faced procurement risks due to increased costs from upstream suppliers and the ongoing impact of the pandemic, prompting it to strengthen its procurement strategies and explore new supply channels[11]. - The company faced challenges due to the COVID-19 pandemic, resulting in reduced demand from downstream customers and decreased international trade[40]. - Increased production costs were attributed to supply chain disruptions and higher procurement costs during the pandemic[41]. - The company emphasizes the importance of innovation and new product development to mitigate procurement price volatility risks[11]. Corporate Social Responsibility and Governance - The company has committed to corporate social responsibility by supporting pandemic relief efforts through donations and material support[13]. - The company emphasizes strict information disclosure and investor relations management, ensuring orderly operations under the new registration system[72]. - The company is committed to fulfilling its obligations regarding immediate return measures to protect investor interests[120]. - The company has made commitments to prevent any interference in its operational management by major shareholders[120]. Research and Development - The company has a strong focus on technological innovation, with 17 authorized patents, including 9 Chinese invention patents and 1 US invention patent[52]. - The company is committed to increasing R&D investment to support the industrialization and marketization of innovative projects[51]. - Research and development expenses were ¥6,415,004.61, down 41.99% from ¥11,058,175.06 in the previous year, due to the scheduling of R&D projects[74]. Environmental Compliance - The company has established an Environmental Protection Management Committee to oversee environmental compliance and pollution control measures[147]. - The company has not reported any major environmental incidents or exceedances of discharge limits during the reporting period[146]. - The company conducted annual emergency drills for environmental incidents to ensure preparedness and response capabilities[150]. Shareholder and Equity Management - The company did not distribute cash dividends or issue bonus shares during the reporting period[14]. - The company plans to continue its strategy of not distributing cash dividends or increasing share capital from capital reserves in the near term[114]. - The company has a three-year unlocking plan for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[162]. - The total number of ordinary shareholders at the end of the reporting period is 21,130[165].

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company’s fixed assets increased by 31.40% compared to the beginning of the period, primarily due to the completion of the expansion project from 3,500 tons to 7,000 tons of gelatin production capacity[44]. - The company’s gelatin production capacity increased to 13,500 tons per year, while collagen production capacity rose to 3,000 tons per year, further solidifying its industry-leading position[43]. - The annual production capacity of gelatin was expanded from 3,500 tons to 7,000 tons, with the project completed in December 2019, achieving 100% of the planned investment[114]. Financial Performance - The company’s operating revenue for 2019 was CNY 491,819,372.27, representing an increase of 8.63% compared to CNY 452,748,251.38 in 2018[26]. - The net profit attributable to shareholders for 2019 was CNY 35,607,138.71, a growth of 4.80% from CNY 33,977,157.88 in the previous year[26]. - The net profit after deducting non-recurring gains and losses decreased by 14.44% to CNY 26,011,731.69 from CNY 30,401,690.85 in 2018[26]. - The net cash flow from operating activities was negative at CNY -41,633,068.00, a decline of 169.39% compared to CNY 60,001,285.47 in 2018[26]. - The total assets at the end of 2019 amounted to CNY 1,314,347,774.95, reflecting a 9.64% increase from CNY 1,198,743,162.74 in 2018[26]. - The net assets attributable to shareholders increased by 32.09% to CNY 991,864,420.48 from CNY 750,879,458.49 in 2018[26]. - The basic earnings per share for 2019 was CNY 0.0704, a decrease of 4.48% from CNY 0.0737 in 2018[26]. - The weighted average return on equity for 2019 was 3.85%, down from 4.61% in 2018[26]. Product Development and Innovation - The company launched a new product line, including collagen peptide juice drinks, targeting the elderly and female markets, amidst intense competition in the consumer goods sector[8]. - The company is focusing on new product development and market expansion in health sectors, particularly in nutrition and bone health markets[7]. - The company successfully developed a new product, compound bone collagen (compound emulsifier), aimed at improving the quality and protein content of frozen and prepared meat products[64]. - The company has developed a collagen peptide preparation method that inhibits cancer cell proliferation, which is crucial for its strategic positioning in the pharmaceutical market[52]. - The company has obtained 3 new invention patents and 1 design patent during the reporting period, enhancing its technological innovation capabilities[66]. Market Strategy and Customer Engagement - The company aims to enhance its brand "Yuan Su Bone Peptide" in Inner Mongolia and surrounding areas, while also expanding its retail collagen protein market share through strategic partnerships[9]. - The company is enhancing its e-commerce and new retail channels to boost sales and customer engagement through a "partner" mechanism[9]. - The company has signed a cooperation agreement with Yicheng (Zhejiang) Trading Co., Ltd. to expand its retail product market[70]. - The company is actively pursuing strategic customer acquisition to solidify its core advantages in the collagen market[135]. - The company plans to enhance its market share by advancing strategic alliances and focusing on differentiated competition in niche markets such as special-purpose gelatin and halal products[135]. Research and Development - The company has invested significantly in R&D, ranking among the top in the industry, and has established stable partnerships with institutions like the Chinese Academy of Sciences to enhance technological advancements[50]. - The company holds 20 authorized patents, including 11 Chinese invention patents and 1 U.S. invention patent, which support its strategic development in the pharmaceutical health sector[52]. - The company has established several research platforms, including key laboratories and technology centers, to bolster its R&D capabilities and innovation[50]. - The company’s R&D investment for the reporting period is ¥17,330,078.65, representing a year-on-year increase of 3.21%[87]. - The number of R&D personnel is 73, making up 10.20% of the total workforce[88]. Risk Management and Operational Strategies - The company is facing procurement risks due to increased costs and supply chain disruptions caused by the pandemic, prompting measures to secure quality raw materials[10]. - The company is committed to optimizing its procurement management to control costs and mitigate risks associated with raw material price fluctuations[10]. - The company has established a pandemic response team to monitor and adjust operational strategies to mitigate the impact of COVID-19 on its business[12]. - The company is focusing on automation and intelligent transformation projects to reduce costs and improve efficiency[70]. - The company has a well-defined emergency response plan for environmental incidents, with annual drills conducted[191]. Corporate Governance and Compliance - The company has made commitments to avoid transferring benefits to other entities or individuals in an unfair manner[152]. - The company has adhered to regulations regarding the reduction of shareholdings by shareholders and senior management[152]. - The company has committed to not engaging in any competing business after its listing[158]. - The company has fulfilled its commitments made during the asset restructuring and non-public issuance of shares, including a lock-up period for newly issued shares[151]. - The company has maintained a continuous audit service with Da Hua Accounting Firm for 8 years[164]. Social Responsibility and Environmental Compliance - The company emphasizes social responsibility, focusing on economic and social benefits while protecting investor rights[184]. - The company donated products worth over 200,000 RMB to support COVID-19 prevention efforts in Baotou[186]. - The company has established an Environmental Protection Management Committee to oversee compliance with environmental regulations[188]. - The company adheres to the national wastewater discharge standards, ensuring no exceedance of pollutant limits[188]. - The company has received multiple honors for its contributions to social welfare and public image[186].

Financial Performance - Total revenue for Q1 2020 was ¥89,993,866.50, a decrease of 20.56% compared to ¥113,291,169.46 in the same period last year[8] - Net profit attributable to shareholders was ¥3,508,687.40, down 53.91% from ¥7,612,512.42 year-on-year[8] - Basic earnings per share decreased by 59.39% to ¥0.0067 from ¥0.0165 in the same period last year[8] - Operating profit was ¥4,202,698.66, down 52.03% year-on-year, while total profit decreased by 52.27% to ¥4,184,391.95[21] - The company reported a net profit of CNY 128,557,649.21, compared to CNY 125,048,961.81 in the previous period, reflecting a growth of approximately 2%[53] - The net profit for the first quarter was CNY 3,508,687.40, down from CNY 7,612,512.42 in the same period last year, representing a decline of about 54%[60] Cash Flow and Liquidity - Net cash flow from operating activities was negative at ¥-2,350,379.61, a decline of 109.13% compared to ¥25,732,244.52 in the previous year[8] - The cash inflow from operating activities was CNY 83,080,412.66, compared to CNY 74,930,997.10 in the previous period, marking an increase of approximately 11%[67] - The total cash outflow from investing activities was 8,250,707.52 yuan, resulting in a net cash flow from investing activities of -8,250,707.52 yuan[72] - The company had a cash increase of 10,611,523.01 yuan during the period, compared to an increase of 189,203,548.49 yuan in the previous period[72] - Total cash and cash equivalents at the end of the period amounted to 61,002,902.85 yuan, down from 250,614,218.96 yuan in the previous period[72] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,339,475,006.30, an increase of 1.91% from ¥1,314,347,774.95 at the end of the previous year[8] - Total liabilities rose to CNY 343,611,088.86 from CNY 322,159,811.22, representing an increase of approximately 6.9%[56] - The total equity of the company reached CNY 999,572,400.74, up from CNY 996,573,716.93, a slight increase of about 0.2%[56] - The total current liabilities were CNY 242,944,983.18, with accounts payable at CNY 143,766,630.86[79] Investment and R&D - R&D expenses increased compared to the previous year, indicating a focus on innovation despite revenue challenges[22] - The company officially launched the "annual production of 2000 tons of collagen protein project," increasing collagen production capacity to 3000 tons/year[30] - The acquisition of Dongbao Datian Bio-Tech Co., Ltd. was completed, enhancing resource utilization and optimizing the company's industrial layout[27][28] - Research and development expenses increased to CNY 2,916,046.19 from CNY 2,618,974.35, showing a growth of about 11%[63] Market and Product Development - The company is advancing the marketization of a new emulsifier product aimed at the frozen prepared meat sector, with plans for significant sales within the year[29] - The company launched a new product line, including collagen peptide juice drinks, targeting the elderly and female markets, amidst a competitive retail environment[33] - The company is focusing on expanding the collagen protein market, leveraging its strong product quality and customer base[30] - The company aims to enhance its brand presence in Inner Mongolia and surrounding areas, leveraging national policies to increase market share in retail collagen products[34] Challenges and Risks - The impact of the COVID-19 pandemic has led to reduced sales volume and increased procurement costs, affecting overall profitability[21] - The company is facing risks related to raw material procurement due to increased costs and supply chain disruptions caused by the pandemic[35] - The company is exploring new sales channels, including e-commerce and community retail, to adapt to changing market conditions and consumer behavior[34] Corporate Governance and Social Responsibility - The company is committed to corporate social responsibility by donating materials and supporting pandemic relief efforts[38] - The company has established a pandemic response team to monitor and adjust operational strategies to mitigate the impact of COVID-19 on production and sales[37] - The company is actively participating in industry standard formulation to enhance product quality and market competitiveness in response to regulatory challenges[36] Financial Reporting and Compliance - The company reported no significant changes in project feasibility during the reporting period[42] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[44][45] - The first quarter report was not audited, which may affect the reliability of the financial data presented[81]

Financial Performance - Operating revenue for the reporting period was ¥108,075,675.55, representing a year-on-year increase of 17.32%[8] - Net profit attributable to shareholders of the listed company was ¥6,179,054.09, up 2.90% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,500,175.84, a slight increase of 0.83% year-on-year[8] - Basic earnings per share for the reporting period were ¥0.0134, an increase of 3.88% year-on-year[8] - The company achieved a revenue of CNY 339,104,382.18 in the first three quarters of 2019, representing a year-on-year growth of 5.22%[25] - Operating profit for the same period was CNY 27,576,557.83, an increase of 2.67% compared to the previous year[25] - The total profit amounted to CNY 30,073,895.18, reflecting a growth of 12.03% year-on-year[25] - The net profit attributable to shareholders reached CNY 25,872,173.47, marking a 13.55% increase from the previous year[25] - The total operating income for the year-to-date period was ¥339,104,382.18, up from ¥322,296,512.05, indicating a growth of approximately 5.2%[62] - The total operating costs for the year-to-date period were ¥314,894,718.74, compared to ¥296,253,938.21 in the previous year, which is an increase of about 6.3%[62] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,250,215,773.63, an increase of 4.29% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥982,713,675.24, reflecting a growth of 30.88% year-on-year[8] - Total current assets decreased to CNY 466.5 million from CNY 477.2 million, a decline of approximately 1.5%[46] - Total non-current assets increased to CNY 783.71 million from CNY 721.54 million, an increase of approximately 8.6%[46] - Total liabilities decreased to CNY 267.50 million from CNY 447.86 million, a decrease of approximately 40.2%[47] - Total equity increased to CNY 982.71 million from CNY 750.88 million, an increase of about 30.8%[48] - The company reported a total liabilities decrease to CNY 267,204,067.60 from CNY 447,188,265.71 year-over-year[53] - The total assets of the company reached CNY 1,255,289,411.45, compared to CNY 1,207,908,499.37 in the previous year[53] Cash Flow - The net cash flow from operating activities showed a significant decline, amounting to -¥55,624,350.37, a decrease of 405.16% compared to the previous year[8] - Cash flow from operating activities showed a net outflow of ¥55,624,350.37, contrasting with a net inflow of ¥18,228,225.75 in the same period last year[73] - Investment activities resulted in a net cash outflow of ¥133,876,970.61, compared to a smaller outflow of ¥25,829,582.16 in the previous year[73] - Financing activities generated a net cash inflow of ¥189,647,263.66, significantly higher than the previous year's inflow of ¥35,350,255.93[73] - The ending cash and cash equivalents balance was ¥67,295,696.78, down from ¥81,931,267.51 in the previous year[73] Research and Development - The company has established a strong focus on R&D, with 12 research labs dedicated to various aspects of collagen and gelatin applications, resulting in 3 new authorized invention patents in 2019[28] - The purification and separation project for bone collagen peptides has shown promising results, indicating that the isolated small peptides promote the proliferation and differentiation of osteoblasts[29] - The company has confirmed the experimental plan for the second animal trial in the study of the tumor-inhibiting mechanism of bone collagen peptides, with patents granted in both China and the US[30] - The electrospun gelatin fiber hemostatic material project is progressing, with the purification plant completed and product registration preparations underway, aiming for production by the end of the year[31] - The development of ultra-low endotoxin gelatin preparation technology is underway, targeting applications in absorbable hemostatic cotton and tissue engineering scaffolds[32] Market Expansion and Product Development - The company is actively pursuing market expansion in the health and beauty sectors, including the development of collagen-based skincare products[27] - The company has successfully developed a new product, "compound bone collagen," primarily used in the frozen prepared meat processing industry, and has obtained the necessary food production license[36] - The company is committed to high-quality development, focusing on the "medical, food, beauty, and health" sectors to enhance product value and meet market demands[35] - The company has initiated research on the high-tech applications of collagen protein in various fields, including biomedicine and food packaging[33] Financial Management - The company's financial expenses decreased by 77.92% to CNY 387,562.32, attributed to reduced bank loans[21] - The company reported a financial expense of -CNY 44,773.89, a significant improvement from CNY 675,494.83 in the previous period[55] - Financial expenses decreased significantly to -¥33,225.44 from ¥675,963.71, indicating improved financial management[59] - The company has implemented a clear and stable cash dividend policy, ensuring transparency and protecting shareholders' rights[39]

Financial Performance - The total operating revenue for the reporting period was CNY 231,028,706.63, a 0.37% increase compared to the same period last year [24]. - The net profit attributable to shareholders of the listed company was CNY 19,693,119.38, representing a 17.36% increase year-on-year [24]. - The net cash flow from operating activities was CNY -49,622,167.79, a decrease of 330.35% compared to the previous year [24]. - The total assets at the end of the reporting period amounted to CNY 1,292,473,846.60, an increase of 7.82% from the end of the previous year [24]. - The net assets attributable to shareholders of the listed company reached CNY 976,117,321.15, reflecting a 30.00% increase compared to the previous year [24]. - The company achieved an operating profit of CNY 20,314,562.63, which is a 1.61% increase from the previous year [34]. - The three period expenses (selling, administrative, and financial expenses) decreased by 4.19% to CNY 20,395,594.52 compared to the previous year [34]. - The company reported a total investment of RMB 74,085.8 million in various projects, with RMB 58,448.9 million already utilized, representing a utilization rate of 78.8% [86]. - The total liabilities decreased to CNY 316,356,525.45 from CNY 447,863,704.25, reflecting a reduction of approximately 29.39% [171]. - The total equity increased to CNY 982,591,679.49 in the first half of 2019, compared to CNY 760,720,233.66 in the same period of 2018, marking a growth of 29.2% [176]. Investment and Expansion - The company raised a total of RMB 232.2 million from a private placement, with the net proceeds allocated entirely to investment projects, aiming for an annual production capacity of 13,500 tons of gelatin and 3,000 tons of collagen after project completion [6]. - The expansion project for gelatin production capacity from 3,500 tons to 7,000 tons is nearing completion, with equipment debugging currently underway [6]. - The company is expanding its production capacity with a project to increase gelatin output from 3,500 tons to 7,000 tons and a new collagen protein project with an annual capacity of 3,000 tons [52]. - The company has invested RMB 36,073,000.00 in a collagen project, with 70.00% of the funding utilized as of the reporting period [80]. - The company has a project for a collagen industry demonstration base, with an investment of RMB 8,572,050.00, which is 78.00% funded [80]. - The company plans to accelerate the investment progress of fundraising projects to quickly realize expected benefits [104]. Research and Development - The company is actively investing in R&D, with a focus on new product development and technology innovation to meet market demands [43]. - The company has developed a patented method for producing collagen peptides with anti-cancer properties, which is expected to enhance its position in the pharmaceutical health sector [45]. - The company has made significant progress in R&D, including the development of a new medical cold compress product and advancements in collagen peptide purification [54]. - Research and development investment surged by 176.86% to RMB 11.06 million, reflecting the company's commitment to enhancing its R&D capabilities [65]. - The company is focusing on research and development of new products and technologies to enhance its market position [138]. Market Strategy - The company plans to enhance market expansion efforts, particularly in the rapidly growing health markets, leveraging the high-quality characteristics of its collagen products [7]. - The company aims to strengthen its brand "Yuan Su Bone Peptide" in Inner Mongolia and surrounding areas, while also developing e-commerce and micro-business channels to increase market share [9]. - The company is focusing on expanding its collagen business, particularly in the Hangzhou market, and is actively engaging in resource integration and partnerships [59]. - The company is committed to aligning its development strategy with the growing health market, particularly in small molecule peptide products [51]. - The company is responding to market challenges by expanding its customer base and exploring new application areas for its products [57]. Financial Management - The company does not plan to distribute cash dividends or issue bonus shares, focusing on reinvestment for growth [12]. - The company has established a comprehensive procurement management system to control supplier selection and procurement costs effectively [10]. - The company is actively investing in high-quality bone particle bases to mitigate procurement price volatility risks associated with raw materials [10]. - The company has implemented a centralized procurement management system to ensure product quality and safety [33]. - The company has made commitments to avoid any competition with its own products and businesses [107]. Environmental and Regulatory Compliance - The company has established an environmental protection management committee and implemented comprehensive environmental monitoring and management systems to ensure compliance with environmental regulations [130]. - The company has successfully maintained all pollutant emissions within the approved limits, with no instances of exceeding discharge standards [130]. - The company reported a total COD discharge of 106.559 tons and ammonia nitrogen discharge of 10.603 tons during the reporting period, adhering to the national wastewater discharge standards [129]. - The company has established emergency response plans for environmental incidents, ensuring preparedness for potential pollution accidents [131]. - There were no penalties or rectification measures required during the reporting period, indicating compliance with regulations [116]. Shareholder and Corporate Governance - The company has committed to fulfilling its obligations to minority shareholders, ensuring timely execution of promises made [109]. - The company has made a commitment to not use company assets for investments unrelated to its responsibilities, ensuring the protection of company interests [102]. - The company has successfully fulfilled its commitments related to the non-public offering of shares, which includes a total of 33,600,000 shares [100]. - The company has ensured that its commitments regarding the non-transfer of shares are being executed normally, with no overdue obligations as of the reporting period [100]. - The company has appointed a new financial director, Hao Haiqing, on April 17, 2019, following the resignation of the previous financial director [161].

Group 1: Event Details - The company will participate in the "2019 Inner Mongolia Listed Companies Investor Online Reception Day" on July 10, 2019, from 15:00 to 17:00 [2] - The event will be held online via the platform provided by Shenzhen Qianjing Network Co., Ltd. [2] - Investors can log in to "Qianjing Roadshow World" (http://rs.p5w.net) to participate in the interactive session [2] Group 2: Company Representatives - Attendees from the company include General Manager Ms. Wang Liping, Deputy General Manager and Board Secretary Mr. Liu Fang, and Chief Financial Officer Mr. Hao Haiqing [2] - The company encourages investors to actively participate in the event [2] Group 3: Assurance of Information Disclosure - The company and its board members guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions [2]

Financial Performance - Total revenue for Q1 2019 was CNY 113,291,169.46, an increase of 14.44% compared to CNY 98,999,088.24 in the same period last year[9] - Net profit attributable to shareholders was CNY 7,612,512.42, up 10.52% from CNY 6,888,130.65 year-on-year[9] - Net cash flow from operating activities reached CNY 25,732,244.52, a significant increase of 366.99% compared to a negative cash flow of CNY -9,637,852.63 in the previous year[9] - Basic earnings per share for the period were CNY 0.0165, representing a 10.74% increase from CNY 0.0149 in the same period last year[9] - The company reported a gross profit margin of approximately 19.1% for Q1 2019, compared to 10.5% in Q1 2018[65] - The net profit for Q1 2019 reached CNY 7,612,512.42, up 10.5% from CNY 6,888,130.65 in the same period last year[67] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,392,384,929.41, reflecting a growth of 16.15% from CNY 1,198,743,162.74 at the end of the previous year[9] - Total liabilities decreased to CNY 413,038,328.78 from CNY 447,863,704.25, indicating a reduction of approximately 7.8%[58] - The company's equity increased to CNY 979,346,600.63 from CNY 750,879,458.49, showing a growth of about 30.4%[58] - Total assets as of March 31, 2019, amounted to CNY 1,400,108,541.55, compared to CNY 1,207,908,499.37 at the end of 2018, reflecting a growth of 15.9%[64] - Total liabilities decreased to CNY 412,614,833.90 from CNY 447,188,265.71, a reduction of 7.7%[63] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,554[13] - The largest shareholder, Inner Mongolia Dongbao Trade Co., Ltd., held 28.46% of the shares, amounting to 149,143,800 shares[13] - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[14] Research and Development - Research and development expenses rose to ¥2,149,549.44, an increase of ¥591,019.93 or 37.92% year-on-year, reflecting higher investment in R&D[21] - Research and development expenses for Q1 2019 were CNY 2,149,549.44, an increase of 37.9% compared to CNY 1,558,529.51 in Q1 2018[65] - The company is advancing the industrialization of the medical collagen project, which has significant market potential in plasma substitutes[24] - The project for the purification and separation of bone collagen peptides has completed core technology verification, paving the way for biological testing[25] Investment and Expansion - The company raised CNY 222,200,000.00 through a non-public issuance of shares[23] - The company plans to expand its production capacity to 13,500 tons of gelatin and 3,000 tons of collagen protein following the completion of fundraising projects[28] - The company has allocated 25,357.3 million CNY for the new gelatin project, with 90.77% of the investment already utilized[49] - The company has also initiated a project to produce 2,000 tons of collagen protein, with 21.19% of the investment completed as of the report date[49] Market Strategy - The company is focusing on high-value markets such as food new materials, health products, and functional foods to increase profit margins[29] - The company aims to establish its collagen product as a leading brand in the market, targeting the elderly and female demographics[38] - The company plans to enhance its e-commerce and micro-business channels, aiming to establish a strong brand image as "China's Good Collagen" and improve customer repurchase rates[39] Financial Management - The company has established a comprehensive procurement management system to control costs and enhance supply chain efficiency[40] - The company is facing procurement price volatility risks due to increased production costs from upstream suppliers amid a recovering domestic economy[39] - The company incurred financial expenses of ¥755,987.33, which is an increase of 61.6% compared to ¥467,516.30 in the previous year[69] Cash Flow - Cash and cash equivalents increased to ¥274,323,770.97, up by ¥175,899,316.87 or 178.72% compared to the beginning of the year due to funds raised from a private placement[20] - The net cash flow from operating activities for Q1 2019 was ¥29,840,366.14, a significant improvement compared to a net outflow of ¥9,621,017.59 in Q1 2018[78] - Total cash inflow from financing activities reached ¥260,715,457.02, compared to ¥25,000,000.00 in the same period last year[79]

Financial Performance - The company's operating revenue for 2018 was CNY 452.75 million, an increase of 27.09% compared to CNY 356.24 million in 2017[22]. - The net profit attributable to shareholders for 2018 was CNY 33.98 million, representing a growth of 51.57% from CNY 22.42 million in 2017[22]. - The net cash flow from operating activities reached CNY 60.00 million, a significant increase of 2,024.98% compared to a negative cash flow of CNY 3.12 million in 2017[22]. - The total assets at the end of 2018 amounted to CNY 1.20 billion, reflecting a growth of 23.39% from CNY 971.54 million at the end of 2017[22]. - The company reported a basic earnings per share of CNY 0.0737, up 51.65% from CNY 0.0486 in the previous year[22]. - Operating profit reached 39.20 million yuan, up 48.18% compared to the previous year[36]. - The company achieved total operating revenue of ¥452,748,251.38 in 2018, representing a year-on-year increase of 27.09% compared to ¥356,244,410.51 in 2017[74]. - The company reported a gross profit margin of 21.54% for its biological and biochemical products, with a slight increase from the previous year[76]. Production Capacity Expansion - The company raised 232 million RMB through a private placement to expand gelatin and collagen production capacity, aiming for an annual production capacity of 13,500 tons of gelatin and 3,000 tons of collagen[6]. - The company is currently completing the expansion of its gelatin production from 3,500 tons to 7,000 tons, with equipment debugging in progress, while the collagen project has completed most of its construction[6]. - The company plans to expand gelatin production capacity from 10,000 tons to 13,500 tons per year and collagen capacity to 3,000 tons per year[42]. - The company has ongoing construction projects, including a new collagen production facility, which is expected to enhance future production capacity[96]. - The company has officially launched a new production line for 3,500 tons of gelatin, further solidifying its leading position in the gelatin industry[115]. Market Strategy and Development - The company plans to enhance its market presence by targeting the health market, particularly focusing on the elderly demographic, leveraging the health benefits of collagen[8]. - The company aims to develop its retail collagen brand "Yuan Su Bone Peptide" and has already penetrated the elderly and female markets with various products[9]. - The company is actively developing new markets for gelatin and collagen, focusing on high-end peptide powder markets to enhance profitability[56]. - The company is focused on establishing a world-class modern collagen biotechnology enterprise, enhancing upstream and downstream industry collaboration, and expanding raw material bases[66]. - The company aims to improve user service management and enhance user loyalty through comprehensive service capabilities and participation in industry exhibitions[69]. Research and Development - The company emphasizes R&D in new technologies and processes, maintaining a leading position in the industry[44]. - The company currently holds 18 authorized patents, including 10 Chinese invention patents and 1 utility model patent, which supports its long-term development in new technologies and products[46]. - The company has made significant advancements in the pharmaceutical health sector, particularly with a patent for a collagen peptide preparation method that inhibits cancer cell proliferation, marking a breakthrough in technology innovation[46]. - The company has published numerous research papers related to gelatin and collagen peptides, indicating its active engagement in scientific research and innovation[47]. - Research and development expenses increased by 30.46% to ¥7,794,456.53, reflecting the company's commitment to enhancing R&D efforts[85]. Financial Management and Shareholder Returns - The company has proposed a profit distribution plan, offering a cash dividend of 0.30 RMB per 10 shares to all shareholders[11]. - In 2018, the company distributed cash dividends of 0.3 RMB per 10 shares, totaling 13,826,223.24 RMB, based on a total share capital of 460,874,108 shares[135]. - The proposed cash dividend for 2018 is 0.3 RMB per 10 shares, amounting to 15,719,823.24 RMB, with a total share capital of 523,994,108 shares[139]. - The company aims to enhance shareholder returns and reduce the risk of dilution for existing shareholders[146]. - The company has committed to strictly adhere to its dividend policy to ensure shareholder returns[145]. Corporate Governance and Compliance - The company appointed Dahua Certified Public Accountants (Special General Partnership) for audit services, with a fee of 330,000 RMB, and has maintained this auditor for 7 years[153]. - The company did not engage in any related party transactions during the reporting period[160]. - The company has committed to not infringe on company interests and to ensure proper management of assets during the reporting period[142]. - The company has established a comprehensive environmental protection management system, ensuring compliance with national wastewater discharge standards without exceeding limits[179]. - The company has received honors for its contributions to social welfare, including participation in disaster relief efforts[175]. Environmental Responsibility - The company has established a comprehensive environmental risk emergency response plan to efficiently handle pollution incidents, ensuring safety and prevention as primary principles[180]. - The emergency response organization is led by the general manager and includes various specialized teams for effective incident management[180]. - The company conducts annual emergency drills related to environmental incidents to enhance the preparedness of all employees[180]. - The environmental self-monitoring program has been effectively implemented, ensuring compliance with environmental regulations[181]. - The main pollutants from the company are COD and ammonia nitrogen, with actual discharge concentrations and amounts within the approved standards[179].

Financial Performance - Operating revenue for the period reached ¥92,121,615.41, reflecting a growth of 14.70% year-on-year[9] - Net profit attributable to shareholders was ¥6,004,834.15, marking a significant increase of 74.75% compared to the same period last year[9] - The net profit after deducting non-recurring gains and losses was ¥5,455,022.34, up 106.95% year-on-year[9] - Basic earnings per share rose to ¥0.0129, an increase of 72.00% compared to the same period last year[9] - The weighted average return on net assets was 0.82%, up from 0.34% in the previous year[9] - The company's operating revenue for Q3 2018 was CNY 322,296,512.05, an increase of 32.89% compared to CNY 242,527,130.13 in the same period last year[23] - Net profit for the third quarter was CNY 4,454,080.01, up 29% from CNY 3,442,673.87 year-over-year[58] - Basic and diluted earnings per share increased to CNY 0.0096 from CNY 0.0075, reflecting a growth of 28%[58] - The net profit for Q3 2018 was CNY 21,123,998.79, an increase of 34.5% compared to CNY 15,677,175.63 in the same period last year[65] - Operating profit for Q3 2018 reached CNY 25,198,515.31, up from CNY 18,542,981.59, reflecting a growth of 36.0% year-over-year[65] Assets and Liabilities - Total assets increased to ¥1,128,510,188.44, a rise of 16.16% compared to the end of the previous year[9] - Cash and cash equivalents increased by 87.80% to ¥102,131,267.51, primarily due to increased sales revenue from gelatin, calcium hydrogen phosphate, and collagen products, as well as a loan of ¥37.5 million from a shareholder[22] - Total current assets increased to 435,668,829.51 yuan from 312,850,730.42 yuan, reflecting a significant growth in liquidity[44] - Total liabilities increased to 388,350,166.34 yuan from 241,780,572.75 yuan, showing a rise in the company's financial obligations[46] - The company's total assets reached 1,128,510,188.44 yuan, up from 971,535,396.60 yuan, indicating overall growth in asset base[46] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥18,228,225.75, a substantial increase of 174.53%[9] - Cash received from sales of goods and services increased by 50.96% to CNY 182,697,338.26, driven by higher sales of gelatin and calcium hydrogen phosphate products[26] - Cash flow from operating activities generated a net amount of CNY 18,228,225.75, a significant recovery from a net outflow of CNY 24,456,863.38 in the previous year[66] - Financing activities generated a net cash inflow of CNY 35,350,255.93, a recovery from a net outflow of CNY 7,210,742.66 in the same period last year[72] Investments and Projects - Long-term equity investments increased by 73.43% to ¥6,944,110.37, reflecting investments in raw material base construction according to the company's overall strategic plan[22] - The company plans to continue expanding its production capacity and investing in new technologies to enhance its market position[20] - The company plans to expand its production capacity from 3,500 tons to 7,000 tons of new process gelatin as part of its non-public stock issuance plan approved by the China Securities Regulatory Commission[28] - The company has received approval for its non-public stock issuance, with a total fundraising target of CNY 36,526.58 million to support its expansion projects[29] - The company is expanding its gelatin production capacity from 3,500 tons to 7,000 tons, with construction nearing completion and equipment installation in the commissioning phase[31] - The collagen project is progressing, with the main construction of the production workshop completed and major equipment being ordered[31] Government Subsidies - The company received government subsidies totaling ¥2,394,868.17, primarily related to asset-related government grants[10] - The company received government subsidies of ¥8.8 million related to assets during the reporting period[22] - The company was awarded 5 million yuan in major special funds for science and technology from the autonomous region[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,723[13] - The largest shareholder, Inner Mongolia Dongbao Trade Co., Ltd., holds 32.14% of the shares, totaling 149,143,800 shares[13] - The total number of restricted shares for executives and other shareholders amounted to 19,067,768 shares, with a three-year unlocking schedule[18] - Cash dividends of 13,826,223.24 yuan were distributed as part of the 2017 profit distribution plan, aligning with the company's dividend policy and shareholder meeting resolutions[38] Inventory and Costs - Inventory rose by 35.28% to ¥209,399,263.71, mainly due to the increase in products, semi-finished products, and finished products following the commissioning of the Binhe New District construction project[22] - Operating costs amounted to ¥85,881,267.45, up from ¥77,174,472.95, indicating an increase of about 11.0%[51] - The company reported a significant increase in inventory stock due to the implementation of an equity incentive plan, totaling CNY 8,455,200.00[23] Research and Development - Research and development expenses were ¥2,095,477.85, down from ¥2,584,482.31, indicating a decrease of about 18.9%[51] - Research and development expenses for the quarter were CNY 5,519,916.44, slightly up from CNY 5,004,085.36 year-over-year[60] Other Financial Metrics - Financial expenses surged by 1267.18% to CNY 1,755,562.62, primarily due to increased bank loans and corresponding interest expenses[23] - The company reported a 100% decrease in investment income, with no income generated from idle funds in the current period[23] - The company recorded investment income of CNY 7.07, a significant decrease from CNY 303,453.69 in the previous year[60] Audit and Future Outlook - The report for Q3 2018 was not audited, indicating that the figures may be subject to change upon final review[73] - Future outlook and strategic initiatives were not detailed in the provided content, suggesting a focus on current performance metrics[60]